Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Antares Pharma Inc (ATRS) Com Stk USD0.01

Sell:$4.63 Buy:$4.64 Change: $0.20 (4.50%)
NASDAQ:1.17%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$4.63
Buy:$4.64
Change: $0.20 (4.50%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$4.63
Buy:$4.64
Change: $0.20 (4.50%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company's subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

Contact details

Address:
SUITE 300, 100 PRINCETON SOUTH
EWING
8628
United States
Telephone:
+1 (609) 3593020
Website:
https://www.antarespharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ATRS
ISIN:
US0366421065
Market cap:
$701.87 million
Shares in issue:
163.23 million
Sector:
Health Care Supplies
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Leonard Jacob
    Independent Chairman of the Board
  • Robert Apple
    President, Chief Executive Officer, Director
  • Fred Powell
    Chief Financial Officer, Executive Vice President
  • Peter Graham
    Executive Vice President, Chief Compliance Officer - Human Resources, General Counsel, Corporate Secretary
  • James Tursi
    Executive Vice President, Head of Research and Development, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.